Effects of chimeric somatostatin–dopamine molecules on human peripheral blood lymphocytes activation

[1]  M. Culler,et al.  Somatostatin and dopamine receptor expression in lung carcinoma cells and effects of chimeric somatostatin-dopamine molecules on cell proliferation. , 2005, American journal of physiology. Endocrinology and metabolism.

[2]  J. Taylor,et al.  Efficacy of chimeric molecules directed towards multiple somatostatin and dopamine receptors on inhibition of GH and prolactin secretion from GH-secreting pituitary adenomas classified as partially responsive to somatostatin analog therapy. , 2005, European journal of endocrinology.

[3]  Ramesh C. Patel,et al.  The Role of Subtype-specific Ligand Binding and the C-tail Domain in Dimer Formation of Human Somatostatin Receptors* , 2004, Journal of Biological Chemistry.

[4]  S. Melmed,et al.  Suppression of rat and human growth hormone and prolactin secretion by a novel somatostatin/dopaminergic chimeric ligand. , 2003, The Journal of clinical endocrinology and metabolism.

[5]  Luigi F Agnati,et al.  Molecular Mechanisms and Therapeutical Implications of Intramembrane Receptor/Receptor Interactions among Heptahelical Receptors with Examples from the Striatopallidal GABA Neurons , 2003, Pharmacological Reviews.

[6]  J. Taylor,et al.  Demonstration of enhanced potency of a chimeric somatostatin-dopamine molecule, BIM-23A387, in suppressing growth hormone and prolactin secretion from human pituitary somatotroph adenoma cells. , 2002, The Journal of clinical endocrinology and metabolism.

[7]  R. Moots,et al.  Dopamine receptor expression on human T- and B-lymphocytes, monocytes, neutrophils, eosinophils and NK cells: a flow cytometric study , 2002, Journal of Neuroimmunology.

[8]  Enrico Gratton,et al.  Ligand binding to somatostatin receptors induces receptor-specific oligomer formation in live cells , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[9]  Michel Bouvier,et al.  Dimerization: an emerging concept for G protein-coupled receptor ontogeny and function. , 2002, Annual review of pharmacology and toxicology.

[10]  Y. Ganor,et al.  Dopamine interacts directly with its D3 and D2 receptors on normal human T cells, and activates β1 integrin function , 2001, European journal of immunology.

[11]  S. Schulz,et al.  Homo- and Heterodimerization of Somatostatin Receptor Subtypes , 2001, The Journal of Biological Chemistry.

[12]  L. Hofland,et al.  Somatostatin and somatostatin receptors in the immune system: a review. , 2000, European cytokine network.

[13]  U. Kumar,et al.  Receptors for dopamine and somatostatin: formation of hetero-oligomers with enhanced functional activity. , 2000, Science.

[14]  U. Kumar,et al.  Subtypes of the Somatostatin Receptor Assemble as Functional Homo- and Heterodimers* , 2000, The Journal of Biological Chemistry.

[15]  Y. Patel.  Somatostatin and Its Receptor Family , 1999, Frontiers in Neuroendocrinology.

[16]  C. Rabourdin-Combe,et al.  sst5 somatostatin receptor mRNA induction by mitogenic activation of human T-lymphocytes , 1999, Peptides.

[17]  M. Cosentino,et al.  Endogenous catecholamine synthesis, metabolism, storage and uptake in human neutrophils. , 1999, Life sciences.

[18]  P. Hayry,et al.  Differential regulation of somatostatin receptor types 1–5 in rat aorta after angioplasty , 1999, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[19]  M. Thangaraju,et al.  Subtype-selective expression of the five somatostatin receptors (hSSTR1-5) in human pancreatic islet cells: a quantitative double-label immunohistochemical analysis. , 1999, Diabetes.

[20]  P. Seeman,et al.  A Transmembrane Domain-derived Peptide Inhibits D1 Dopamine Receptor Function without Affecting Receptor Oligomerization* , 1998, The Journal of Biological Chemistry.

[21]  U. Kumar,et al.  Expression of the Five Somatostatin Receptor (SSTR1-5) Subtypes in Rat Pituitary Somatotrophes: Quantitative Analysis by Double-Label Immunofluorescence Confocal Microscopy. , 1997, Endocrinology.

[22]  C. Larsson,et al.  Acute effects of D1- and D2-receptor agonist and antagonist drugs on somatostatin binding, inhibition of adenylyl cyclase activity and accumulation of inositol 1,4,5-trisphosphate in the rat striatum. , 1997, Brain research. Molecular brain research.

[23]  E. Rodríguez-Martín,et al.  Dopamine enhances somatostatin receptor‐mediated inhibition of adenylate cyclase in rat striatum and hippocampus , 1997, Journal of neuroscience research.

[24]  Y. Qiu,et al.  Immunoregulatory role of neurotransmitters. , 1996, Advances in neuroimmunology.

[25]  J. Bergquist,et al.  Discovery of endogenous catecholamines in lymphocytes and evidence for catecholamine regulation of lymphocyte function via an autocrine loop. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[26]  E. Krenning,et al.  Somatostatin and the immune and haematopoetic system; a review , 1994, European journal of clinical investigation.

[27]  C. B. Srikant,et al.  Expression of multiple somatostatin receptor genes in AtT-20 cells. Evidence for a novel somatostatin-28 selective receptor subtype. , 1994, The Journal of biological chemistry.

[28]  T. Lahiri,et al.  Uptake and biodistribution of dopamine in bone marrow, spleen and lymph nodes of normal and tumor bearing mice. , 1993, Life sciences.

[29]  S. Vincent,et al.  The effects of cysteamine on dopamine-mediated behaviors: Evidence for dopamine-somatostatin interactions in the striatum , 1986, Pharmacology Biochemistry and Behavior.

[30]  O. Hornykiewicz.  Dopamine (3-hydroxytyramine) and brain function. , 1966, Pharmacological reviews.